SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
IPO Year: 2018
Exchange: NASDAQ
Website: si-bone.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2024 | $27.00 → $19.00 | Buy | Needham |
| 3/28/2024 | $25.00 | Overweight | Piper Sandler |
| 10/12/2022 | $20.00 | Buy | Jefferies |
| 4/7/2022 | $34.00 | Overweight | Cantor Fitzgerald |
| 3/1/2022 | $30.00 → $28.00 | Overweight | Morgan Stanley |
| 1/18/2022 | $43.00 → $36.00 | Buy | B of A Securities |
| 12/21/2021 | $35.00 → $30.00 | Buy | Truist Securities |
| 11/9/2021 | $42.00 → $36.00 | Market Outperform | JMP Securities |
| 8/3/2021 | $41.00 → $40.00 | Overweight | Morgan Stanley |
| 8/3/2021 | $42.00 → $37.00 | Buy | Needham |
SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, December 4, 2024, at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://event.webcasts.com/starthere.jsp?ei=1696941&tp_key=589204a98b. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast
SANTA CLARA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights (any comparisons are to the prior year period) Worldwide revenue of $40.3 million, representing growth of ~19% U.S. revenue of $38.3 million, representing growth of ~18%Gross margin of ~79%Net loss of $6.6 million, representing an improvement of ~34%Adjusted EBITDA loss of $0.2 million, representing an improvement of ~94%Ended the quarter with $150.8 million in cash and equivalents, representing $0.7 million in net
SANTA CLARA, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/b8oqnu9r. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be archived and availa
SANTA CLARA, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, September 4, 2024, at 10:45 a.m. Eastern Time / 7:45 a.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://url.us.m.mimecastprotect.com/s/r-x6CjRnDNsnPR3wF7sxumTszz?domain=cc.webcasts.com. Live audio of the webcast will be available on the "Investors" section of the company's w
SANTA CLARA, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will be participating in the upcoming 2024 Canaccord Genuity 44th Annual Growth Conference in Boston. Management will be hosting a fireside chat on Wednesday, August 14th, 2024, at 3:30 p.m. Eastern Time/ 1:30 p.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://url.us.m.mimecastprotect.com/s/1f7GCNk84yt0E1qNsm3zxj?domain=wsw.com. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The
Increases 2024 revenue guidance to $165 million - $167 millionExpects to achieve positive Adjusted EBITDA in Fourth Quarter 2024 SANTA CLARA, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights (comparisons are to the prior year period) Worldwide revenue of $40.0 million, representing growth of ~20% U.S. revenue of $37.8 million, representing growth of ~21%Gross margin of ~79%Net loss of $8.9 million, representing an improvement of ~20%Adjusted EBITDA loss of $2.7 million, representing an i
SANTA CLARA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2024 after market close on Monday, August 5, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/bdg2s7zw. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast w
SANTA CLARA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2024 Truist Securities MedTech Conference in Boston. Management will be hosting a fireside chat on Tuesday, June 18, at 3:40 p.m. Eastern Time / 12:40 p.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://wsw.com/webcast/truist5/sibn/2067200. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast w
SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $37.9 million, representing growth of ~16%U.S. revenue of $35.4 million, representing growth of ~16%Gross margin of ~79%Over 1,100 U.S. active physicians, representing an increase of ~16%Strong liquidity with $157.8 million in cash and equivalents Recent Operational Highlights Completed the first pelvic fixation procedure with sm
SANTA CLARA, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2024 BofA Securities Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 14, at 2:20 p.m. Eastern Time / 11:20 a.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://bofa.veracast.com/webcasts/bofa/healthcare2024/idwLc6ml.cfm. Live audio of the webcast will be available on the "Investors" section of the company's website at: www
SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, December 4, 2024, at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://event.webcasts.com/starthere.jsp?ei=1696941&tp_key=589204a98b. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast
SANTA CLARA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights (any comparisons are to the prior year period) Worldwide revenue of $40.3 million, representing growth of ~19% U.S. revenue of $38.3 million, representing growth of ~18%Gross margin of ~79%Net loss of $6.6 million, representing an improvement of ~34%Adjusted EBITDA loss of $0.2 million, representing an improvement of ~94%Ended the quarter with $150.8 million in cash and equivalents, representing $0.7 million in net
SANTA CLARA, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for the iFuse Bedrock Granite™ (Granite) system, used for pelvic fixation and sacroiliac joint fusion in conjunction with lumbar spinal fusion procedures, under the Medicare Hospital Outpatient Prospective Payment System. TPT payment status, which will be effective up to three years beginning January 1, 2025, allows patient access to new and innovative technology l
SANTA CLARA, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/b8oqnu9r. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be archived and availa
SANTA CLARA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced first-in-patient procedures with the FDA-designated breakthrough device, iFuse TORQ TNT™ Implant System (TNT). Designed to address the anatomic and biomechanical challenges of pelvic fragility fractures, particularly in patients with poor bone quality, TNT offers a significant advancement over traditional cannulated screws. TNT, which received 510(k) clearance in August 2024 and was awarded Breakthrough Device Designation by the FDA, is the first 3D-printed transiliac-transsacr
SANTA CLARA, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, September 4, 2024, at 10:45 a.m. Eastern Time / 7:45 a.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://url.us.m.mimecastprotect.com/s/r-x6CjRnDNsnPR3wF7sxumTszz?domain=cc.webcasts.com. Live audio of the webcast will be available on the "Investors" section of the company's w
SANTA CLARA, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, announces FDA 510(k) clearance of the iFuse TORQ TNT™ Implant System (TNT). The TNT implant system is designed to meet the specific anatomical and bone mineral density needs of the sacrum and ilium and will serve as the next generation technology for pelvic fragility fracture fixation and sacroiliac joint fusion. TNT includes a porous threaded implant with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and into the contralateral ilium (through
SANTA CLARA, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will be participating in the upcoming 2024 Canaccord Genuity 44th Annual Growth Conference in Boston. Management will be hosting a fireside chat on Wednesday, August 14th, 2024, at 3:30 p.m. Eastern Time/ 1:30 p.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://url.us.m.mimecastprotect.com/s/1f7GCNk84yt0E1qNsm3zxj?domain=wsw.com. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The
Increases 2024 revenue guidance to $165 million - $167 millionExpects to achieve positive Adjusted EBITDA in Fourth Quarter 2024 SANTA CLARA, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights (comparisons are to the prior year period) Worldwide revenue of $40.0 million, representing growth of ~20% U.S. revenue of $37.8 million, representing growth of ~21%Gross margin of ~79%Net loss of $8.9 million, representing an improvement of ~20%Adjusted EBITDA loss of $2.7 million, representing an i
SANTA CLARA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2024 after market close on Monday, August 5, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/bdg2s7zw. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast w
Morgan Stanley analyst Drew Ranieri maintains SI-BONE (NASDAQ:SIBN) with a Overweight and lowers the price target from $25 to $21.
Morgan Stanley analyst Drew Ranieri maintains SI-BONE (NASDAQ:SIBN) with a Overweight and lowers the price target from $26 to $25.
JMP Securities analyst David Turkaly reiterates SI-BONE (NASDAQ:SIBN) with a Market Outperform and maintains $32 price target.
6 analysts have expressed a variety of opinions on SI-BONE (NASDAQ:SIBN) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 1 2 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $25.67, along with a high estimate of $27.00 and a low estimate of $24.00. Observing a 1.34% increase, the
Needham analyst David Saxon reiterates SI-BONE (NASDAQ:SIBN) with a Buy and maintains $27 price target.
SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.32) by 15.62 percent. This is a 15.62 percent increase over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $37.867 million which beat the analyst consensus estimate of $36.494 million by 3.76 percent. This is a 15.77 percent increase over sales of $32.708 million the same period last year.
Gainers Agape ATP (NASDAQ:ATPC) shares rose 23.0% to $0.32 during Monday's after-market session. The market value of their outstanding shares is at $24.9 million. FibroGen (NASDAQ:FGEN) shares increased by 20.68% to $1.4. The market value of their outstanding shares is at $139.2 million. As per the news, the Q1 earnings report came out today. RxSight (NASDAQ:RXST) shares rose 11.39% to $70.0. The company's market cap stands at $2.6 billion. As per the news, the Q1 earnings report came out today. Innovative Eyewear (NASDAQ:LUCY) shares increased by 10.81% to $0.25. The market value of their outstanding shares is at $3.2 million. Hims & Hers Health (NYSE:HIMS) shares increased by 10.72% t
Needham analyst David Saxon reiterates SI-BONE (NASDAQ:SIBN) with a Buy and maintains $27 price target.
144 - SI-BONE, Inc. (0001459839) (Subject)
10-Q - SI-BONE, Inc. (0001459839) (Filer)
8-K - SI-BONE, Inc. (0001459839) (Filer)
SCHEDULE 13G - SI-BONE, Inc. (0001459839) (Subject)
144 - SI-BONE, Inc. (0001459839) (Subject)
144 - SI-BONE, Inc. (0001459839) (Subject)
10-Q - SI-BONE, Inc. (0001459839) (Filer)
8-K - SI-BONE, Inc. (0001459839) (Filer)
8-K - SI-BONE, Inc. (0001459839) (Filer)
144 - SI-BONE, Inc. (0001459839) (Subject)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)
SC 13G - SI-BONE, Inc. (0001459839) (Subject)
SC 13G - SI-BONE, Inc. (0001459839) (Subject)
SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)
SC 13G - SI-BONE, Inc. (0001459839) (Subject)
SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)
SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)
SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)
SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)
SC 13G - SI-BONE, Inc. (0001459839) (Subject)
Needham reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $19.00 from $27.00 previously
Piper Sandler initiated coverage of SI-BONE with a rating of Overweight and set a new price target of $25.00
Jefferies initiated coverage of SI-BONE with a rating of Buy and set a new price target of $20.00
Cantor Fitzgerald resumed coverage of SI-BONE with a rating of Overweight and set a new price target of $34.00
Morgan Stanley reiterated coverage of SI-BONE with a rating of Overweight and set a new price target of $28.00 from $30.00 previously
B of A Securities reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $36.00 from $43.00 previously
Truist Securities reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $30.00 from $35.00 previously
JMP Securities reiterated coverage of SI-BONE with a rating of Market Outperform and set a new price target of $36.00 from $42.00 previously
Morgan Stanley reiterated coverage of SI-BONE with a rating of Overweight and set a new price target of $40.00 from $41.00 previously
Needham reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $37.00 from $42.00 previously
Mainstay Medical Holdings plc today announced the appointment of two new independent members to the company's board of directors, Jeffrey Dunn and Eric Major. These appointments bring Mainstay's total board membership to seven. "We are pleased to welcome these two transformational business leaders as new independent directors on the Board," said David Brabazon, Chairman of the Mainstay Board of Directors. "Their deep experience will be invaluable to Mainstay as we grow our business and pursue our mission to serve patients with intractable chronic low back pain." "As our business evolves and we continue to focus on commercial growth, broadening the industry expertise on our Board will help
SANTA CLARA, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the appointment of Anshul Maheshwari as the company's Chief Financial Officer effective April 20, 2021, and the addition of Helen Loh and Laura Francis to its Board of Directors effective April 18, 2021. The appointment of Mr. Maheshwari completes the recently announced senior leadership transition which includes Laura Francis succeeding Jeff Dunn as Chief Executive Officer, and Tony Recupero becoming President, Commercial Operations. Jeff Dunn will remain with the compa
Laura Francis to Become Chief Executive Officer; Jeff Dunn to Become Executive Chairman; and Tony Recupero to Become President. SANTA CLARA, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN) (“SI-BONE” or the “Company”), a Silicon Valley-based medical device company focused on the development of implantable devices used in the surgical treatment of the sacropelvic anatomy, today announced its intention to appoint Laura Francis as Chief Executive Officer and to the board of directors. Laura Francis currently serves as SI-BONE’s Chief Financial Officer and Chief Operating Officer. As CEO, Laura Francis will succeed Jeff Dunn, who will remain with the Company as Execut